Results 41 to 50 of about 34,802 (246)

Association Between Opioid Dosage Tapering and Opioid Overdose Among Long-Term Higher-Dose Opioid Users

AJPM Focus
Introduction: There has been a steady decline in the national opioid-dispensing rate in recent years. However, emerging evidence that suggests that abrupt discontinuation of opioids for pain may increase overdose risk.
Hui Zhou, PhD, Katherine J. Pak, MS, Fagen Xie, PhD, Craig K. Chang, MD, Patricia L. Gray, PharmD, Deborah S. Ling-Grant, PhD, Joanna L. Barreras, PhD, MSW, Steven G. Steinberg, MD, Rulin C. Hechter, MD, PhD   +8 more
doaj   +1 more source

Organ‐specific redox imbalances in spinal muscular atrophy mice are partially rescued by SMN antisense oligonucleotides

FEBS Letters, EarlyView.
We identified a systemic, progressive loss of protein S‐glutathionylation—detected by nonreducing western blotting—alongside dysregulation of glutathione‐cycle enzymes in both neuronal and peripheral tissues of Taiwanese SMA mice. These alterations were partially rescued by SMN antisense oligonucleotide therapy, revealing persistent redox imbalance as ...
Sofia Vrettou, Brunhilde Wirth
wiley   +1 more source

Microbiome−host proteostasis crosstalk—An emerging perspective on mechanisms and interventions toward healthy longevity

FEBS Letters, EarlyView.
Proteostasis and the gut microbiota play a key role in shaping host physiology. Microbiota‐derived metabolites, vitamins, and RNA modulate host proteostasis. Findings from model systems, including C. elegans, indicate microbes can either stabilize or disrupt host proteostasis.
Abhishek Anil Dubey, Maria Ermolaeva
wiley   +1 more source

Primary Care Opioid Taper Plans Are Associated with Sustained Opioid Dose Reduction [PDF]

Journal of General Internal Medicine, 2020
Primary care providers prescribe most long-term opioid therapy and are increasingly asked to taper the opioid doses of these patients to safer levels. A recent systematic review suggests that multiple interventions may facilitate opioid taper, but many of these are not feasible within the usual primary care practice.To determine if opioid taper plans ...
Mark D. Sullivan, Denise Boudreau, Laura Ichikawa, David Cronkite, Ladia Albertson-Junkans, Gladys Salgado, Michael VonKorff, David S. Carrell   +7 more
openaire   +2 more sources

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial

Trials, 2022
Background Biological disease-modifying anti-rheumatic drugs (bDMARDs) are effective in the treatment of rheumatoid arthritis (RA) but are expensive and increase the risk of infection. Therefore, in patients with a stable low level of disease activity or
Marianne A. Messelink, Matthijs S. van der Leeuw, Alfons A. den Broeder, Janneke Tekstra, Marlies C. van der Goes, Marloes W. Heijstek, Floris Lafeber, Paco M. J. Welsing   +7 more
doaj   +1 more source

Three phosphatase families form a community: The phosphohydrolases that act upon inositol pyrophosphates

FEBS Letters, EarlyView.
Inositol pyrophosphates are energy‐rich signaling molecules that perform critical functions in cells. Three different families of phosphatases hydrolyze the β phosphate of the inositol pyrophosphate molecules: two have narrow specificities and one is promiscuous.
Ronda J. Rolfes
wiley   +1 more source

Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes

Lupus Science and Medicine
Objective To determine the feasibility and risk of flares by achieving successful glucocorticoid (GC) tapering during the first year of juvenile SLE and the value of early achievement of childhood lupus low disease activity state (cLLDAS).Methods The ...
Seza Ozen, Ozgur Kasapcopur, Ozge Basaran, Sezgin Sahin, Ozge Baba, Hakan Kısaoğlu, Dilara Unal, Umit Gul, Mukaddes Kalyoncu   +8 more
doaj   +1 more source

Feasibility study of a Behavioural Intervention for Opioid Reduction (BIOR) for patients with chronic non-cancer pain in primary care: a protocol

BMJ Open, 2023
Introduction Around 30%–50% of adults suffer moderate to severe chronic pain not caused by cancer. Significant numbers are treated with opioids which over time may cease to be effective and produce side effects (eg, nausea, drowsiness and constipation ...
Bernhard Frank, Helen M Poole, Emma Begley, Aimee Woods, Andreia Ramos-Silva, Mike Merriman, Roisin McCulough, Catharine Montgomery   +7 more
doaj   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)

RMD Open, 2023
Introduction Glucocorticoids are still a mainstream of rheumatoid arthritis (RA) treatment. Reducing glucocorticoids should be attempted in all patients. However, choosing the right tapering strategy is challenging.
Giovanni Adami, Angelo Fassio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana, Camilla Benini, Davide Bertelle, Francesca Pistillo   +7 more
doaj   +1 more source